Autism Stem Cell Treatment in Utah: What Families Should Know About the Research

Families researching autism often encounter regenerative medicine and stem cell therapy online.

Some studies have explored whether cell-based therapies could influence areas such as social communication, adaptive behavior, or other autism-related outcomes. Researchers have been particularly interested in possible relationships between immune signaling, inflammation, and autism in certain subgroups.

But the research is still developing.

There is currently no FDA-approved stem cell therapy for autism, and stem cell treatment has not been proven to cure autism. FDA specifically identifies autism as a condition for which regenerative medicine therapies have not been approved. (U.S. Food and Drug Administration)

For families considering stem cell treatment in Utah, it is important to understand what has actually been studied, what results have been mixed, and how Utah law differs from FDA approval.

Quick Answer: Are Stem Cells Approved for Autism?

No.

There is currently no FDA-approved stem cell or regenerative medicine treatment for autism. (U.S. Food and Drug Administration)

Researchers have conducted human trials involving:

• Autologous umbilical cord blood
• Donor umbilical cord blood
• Umbilical cord tissue-derived mesenchymal stromal cells
• Bone-marrow-derived cell products

Results have varied.

Some small studies have reported improvements in selected outcomes, while larger randomized studies have failed to demonstrate improvement in their primary autism outcomes.

That means the evidence should currently be considered investigational rather than established treatment evidence.

Why Are Researchers Studying Cell Therapy for Autism?

Autism spectrum disorder is a neurodevelopmental condition.

There is no single biological cause of autism, and autistic people differ significantly in:

• Communication
• Sensory processing
• Learning
• Behavior
• Intellectual ability
• Medical conditions
• Support needs

One area of research has examined whether immune and inflammatory differences may be relevant in some autistic individuals.

Because mesenchymal stromal cells and other cell products can interact with immune signaling, researchers have explored whether those properties might affect certain autism-related outcomes.

That is a scientific hypothesis.

It does not mean autism is simply an inflammatory condition or that reducing inflammation has been proven to treat autism.

What Have Human Studies Found?

A Large Duke Randomized Trial

One of the most important studies enrolled 180 children ages 2 to 7.

Children received either:

• Their own umbilical cord blood
• Donor umbilical cord blood
• Placebo

The study was randomized and double-blinded.

Overall, researchers found no evidence that cord-blood infusion improved the primary outcome of social communication, and there was no overall improvement in the main secondary measures of autism symptoms or vocabulary compared with placebo. (PubMed)

Exploratory findings suggested possible changes in certain measures among children without intellectual disability, but the investigators concluded that more research was needed. (PubMed)

That distinction is important.

The overall trial was not positive for its primary endpoint.

An Earlier Placebo-Controlled Trial

A smaller randomized crossover trial studied 29 young children receiving their own stored umbilical cord blood.

Researchers observed trends in some measures but found no statistically significant treatment differences for the study endpoints. (PubMed)

Again, the investigators called for further tightly controlled research rather than concluding that the treatment was established.

Umbilical Cord Tissue MSC Research

Duke researchers have also investigated human umbilical cord tissue-derived mesenchymal stromal cells, which are different from cord blood.

A phase I study treated 12 children with one to three IV doses of donor-derived cord-tissue MSCs.

The primary purpose was safety and feasibility.

The treatment was generally tolerated, although five children developed new anti-HLA antibodies. Six of the 12 participants improved on at least two autism-specific measures. Because the study was small and open-label with no placebo group, it could not establish effectiveness. (PubMed)

The authors specifically stated that efficacy needed to be tested in a randomized placebo-controlled trial. (PubMed)

What Does the Newer 2026 Research Show?

Research is still continuing.

A randomized, double-blind study published in June 2026 evaluated 34 children ages 3 to 8 who had both autism and defined peripheral immune dysregulation.

Seventeen received multiple IV infusions of allogeneic umbilical cord blood mononuclear cells, while 17 received placebo. Both groups continued rehabilitation therapy. (PubMed)

Researchers reported a statistically significant difference on the Social Responsiveness Scale-2 total score and social-cognition domain at 13 weeks. They described the results as showing preliminary safety and potential efficacy. (PubMed)

That study is interesting, but several limitations matter:

• Only 34 children participated
• Follow-up was short
• It involved a specifically selected subgroup with immune dysregulation
• It used umbilical cord blood mononuclear cells
• It did not use the same product as an umbilical cord tissue MSC therapy
• It was conducted at a single center

So it would be inappropriate to conclude from this one study that:

“Stem cells have now been proven to treat autism.”

They have not.

The study instead provides a reason for additional research.

Cord Blood Is Not the Same as Umbilical Cord MSCs

This is especially important when reading autism research.

You may find a study involving:

umbilical cord blood

and then find a clinic offering:

umbilical cord tissue-derived MSCs.

Those are not the same product.

Cord blood contains blood-forming and immune cell populations.

Wharton’s jelly and other umbilical cord tissues can be used as sources of mesenchymal stromal cells.

Research involving one cannot automatically establish the effectiveness of the other.

The same applies to:

• Bone marrow
• Placental cells
• Cord blood mononuclear cells
• Culture-expanded MSCs

When a clinic cites an autism study, ask:

“Does this study actually use the same type of cells you’re offering?”

What Treatments Have the Most Established Role in Autism Care?

Current autism care typically focuses on an individual’s specific needs rather than attempting to “cure autism.”

CDC describes evidence-supported approaches that may include:

• Behavioral intervention
• Speech and language therapy
• Occupational therapy
• Developmental approaches
• Educational support
• Psychological treatment
• Medications for certain co-occurring symptoms or conditions

CDC notes that behavioral approaches currently have the strongest evidence for addressing autism-related symptoms and skills. (CDC)

Experimental regenerative therapy should not replace therapies, medical care, educational services, or other supports that are helping an autistic person function and thrive.

Is Autism Stem Cell Treatment Available in Utah?

Utah has a state law addressing non-FDA-approved stem cell therapies.

Utah Code § 58-1-512, effective in its current form May 6, 2026, allows an appropriately scoped healthcare provider to perform certain non-FDA-approved stem cell therapies provided specific disclosure and informed-consent requirements are followed. (Utah Legislature)

The law requires providers to disclose clearly that the therapy has not been approved by the FDA. (Utah Legislature)

That state framework is important.

But it does not mean:

Utah has proven stem cells treat autism.

It also does not convert a non-FDA-approved treatment into an FDA-approved treatment.

Families should understand the clinical evidence and federal regulatory status separately from Utah’s state disclosure framework.

What Should Parents Ask Before Considering Treatment?

If your family is researching regenerative treatment for autism, some of the most useful questions are:

What exact cells are being used?

Cord blood?

Cord tissue MSCs?

Another source?

What human study supports this exact product?

Ask to see the original research.

Was the study randomized and placebo-controlled?

Open-label studies are useful for early safety research but are much weaker for determining effectiveness.

Did the study achieve its primary endpoint?

Do not focus only on exploratory findings or subgroup analyses.

Is the product FDA-approved for autism?

Currently, the answer for regenerative stem cell therapies is no. (U.S. Food and Drug Administration)

What outcome are we trying to improve?

For example:

• Communication?
• Adaptive functioning?
• A specific co-occurring medical concern?

The goal should be specific and measurable.

What can’t treatment promise?

A responsible provider should be able to discuss uncertainty and limitations.

What established supports should continue?

Regenerative treatment should not require abandoning therapies that already benefit the patient.

Frequently Asked Questions

Can stem cells cure autism?

There is currently no evidence establishing stem cell therapy as a cure for autism.

No regenerative stem cell therapy is FDA-approved to treat autism. (U.S. Food and Drug Administration)

Have stem cells been studied for autism?

Yes.

Human research has studied cord blood, cord-tissue MSCs, bone-marrow-derived products, and other cell therapies.

Results remain mixed.

Did the Duke autism stem cell trial work?

The large randomized phase II Duke study involving 180 children found no overall improvement in its primary socialization outcome or key secondary autism outcomes compared with placebo. (PubMed)

Exploratory subgroup findings led investigators to recommend further research.

Are there newer positive studies?

Yes, some smaller studies have reported potentially encouraging findings.

A 2026 randomized study of 34 children with autism and peripheral immune dysregulation reported improvement on selected social-responsiveness measures after donor cord-blood mononuclear-cell infusions. The researchers characterized the findings as preliminary. (PubMed)

Larger independent trials are still needed.

Are umbilical cord blood and umbilical cord stem cells the same thing?

No.

Cord blood and cord-tissue-derived MSC products contain different cell populations and should not be treated as interchangeable.

Is stem cell treatment for autism FDA-approved?

No. FDA specifically states that regenerative medicine therapies have not been approved to treat autism. (U.S. Food and Drug Administration)

Is stem cell therapy legal in Utah?

Utah has a state framework allowing certain non-FDA-approved stem cell therapies when providers meet disclosure, consent, and other requirements under Utah Code § 58-1-512. (Utah Legislature)

That should not be confused with FDA approval or proof of effectiveness for autism.

Research Is Ongoing, but Expectations Matter

There is legitimate scientific interest in cell-based therapies and autism.

There are human trials.

There are biological hypotheses worth studying.

And there are some newer findings that justify continued research.

But the evidence in 2026 does not support promising families that stem cells will cure autism or reliably improve autism-related symptoms.

A responsible discussion should include both sides:

Why researchers are interested

and

why the treatment remains investigational.

The Re/ Clinic in Sandy, Utah offers regenerative medicine consultations and IV stem cell therapy. Families interested in discussing emerging regenerative research should receive individualized medical counseling, clear information about the product being considered, realistic expectations, alternatives, risks, and the treatment’s FDA status. (The Re/ Clinic)

Call: 385-240-1000
Location: 9035 S 700 E, Sandy, UT 84070

References

1. Dawson G, Sun JM, Baker J, et al. A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder. Journal of Pediatrics. 2020. The 180-participant randomized trial did not demonstrate improvement in its primary outcome or key secondary autism outcomes overall. (PubMed)
2. Chez M, Lepage C, Parise C, et al. Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. Stem Cells Translational Medicine. 2018. No statistically significant differences were found for the study endpoints. (PubMed)
3. Sun JM, Dawson G, Franz L, et al. Infusion of Human Umbilical Cord Tissue Mesenchymal Stromal Cells in Children With Autism Spectrum Disorder. Stem Cells Translational Medicine. 2020. Phase I open-label safety and feasibility study involving 12 children. (PubMed)
4. Zhang Z, Wang G, Han F, et al. Efficacy and safety of allogeneic umbilical cord blood mononuclear cells therapy in children with autism spectrum disorder and immune dysregulation. Stem Cell Research & Therapy. June 2026. Small randomized placebo-controlled trial reporting preliminary positive findings in a selected subgroup. (PubMed)
5. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. FDA specifically states that regenerative medicine therapies are not approved to treat autism. (U.S. Food and Drug Administration)
6. Centers for Disease Control and Prevention. Treatment and Intervention for Autism Spectrum Disorder. Current overview of behavioral, developmental, educational, pharmacologic, and other established autism supports. (CDC)
7. Utah Code § 58-1-512. Stem Cell Disclosure. Current version effective May 6, 2026. (Utah Legislature)

Utah Stem Cell Therapy Notice

THIS NOTICE MUST BE PROVIDED TO YOU UNDER UTAH LAW.

This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration.

You are encouraged to consult with your primary care provider before undergoing a stem cell therapy. (Utah Legislature)